ArticleJournal of inflammation research2026
Serum Hepatocyte-Derived Fibrinogen-Related Protein-1: A Novel Biomarker for Severity and Clinical Outcome in Acute Ischemic Stroke.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This work was designed to investigate the expression of hepatocyte-derived fibrinogen-related protein-1 (HFREP1) and its clinical value in patients with first-ever acute ischemic stroke (AIS). Methods: A total of 222 newly diagnosed patients with first-onset AIS admitted to the Encephalopathy Center of Jiangsu Province Hospital of Chinese Medicine from April 2023 and September 2024 were enrolled as the AIS group. Besides, 89 healthy individuals matched for age and sex were included in the control cohort. Baseline demographic characteristics and laboratory indicators were gathered from all enrolled subjects. Serum HFREP1 levels were determined using the enzyme-linked immunosorbent assay (ELISA) method. Spearman correlation analysis was adopted to analyze the correlation between HFREP1 expression and other laboratory indexes. Logistic regression was applied to identify independent factors affecting the severity and short-term prognosis of AIS. Receiver operating characteristic (ROC) curve analysis was further performed to assess the predictive efficacy of serum HFREP1 for AIS severity and short-term clinical outcome. Results: Compared with the control group, the AIS group presented obviously higher serum HFREP1 concentrations ( Conclusion: Elevated serum HFREP1 level might act as a novel and promising early biomarker for evaluating disease severity and predicting poor short-term prognosis in patients with first-onset AIS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.